BRAF and melanoma: In BRAF-mutant melanomas, CAF-derived HGF has been implicated in resistance to BRAF inhibitors by reactivating the MAPK signaling pathway, thereby allowing melanoma cells to evade therapeutic pressure [24,44,45] (Figure 1).